Serial injections of oncolytic virus therapy shows promise in patients with glioblastoma, opening the door to longitudinal study designs that could yield rich insights. News and Views from John D. Christie & E. Antonio Chiocca BrighamWomens harvardmed
The 5-year survival rate for patients diagnosed with glioblastoma , a highly invasive brain cancer, is less than 10%. Upon initial diagnosis, treatment consists of neurosurgical resection followed first by chemoradiation and then by adjuvant temozolomide chemotherapy, which can also be aided by tumor-treating fields
. The presence of a mutant isocitrate dehydrogenase gene and/or of a hypermethylated promoter for methylguanine methyltransferase portend improved responses to therapy and improved survival, but even these favorable biological features do not forestall the inevitable neoplastic recurrence. Tumors without these favorable characteristics inevitably recur within 6–9 months
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Financing the health needs of Ukrainian refugees - Nature MedicineFinancing the health needs of Ukrainian refugees. Correspondence from Wu Zeng Georgetown.
続きを読む »
Hepatitis B: a new weapon against an old enemy - Nature MedicineNew strategies based on nucleic acid technologies are being exploited to treat chronic hepatitis B—a pilot clinical study of antisense oligonucleotide treatment shows the potential promise of this approach.
続きを読む »
Global elimination of hepatitis C virus by 2030: why not? - Nature MedicineThe World Health Organization’s targets for eliminating hepatitis C virus by 2030 have been deemed ambitious by many. However, we believe they are achievable, provided they are supported by global commitment.
続きを読む »
Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial - Nature MedicineA first-in-human study of an antisense oligonucleotide targeting hepatitis B virus RNA provides initial insights into this potential new therapeutic modality for individuals with chronic HBV infection ASO HKUniversity NMEDClinical WorldHepatitisDay
続きを読む »
People - Nature BiotechnologyPeople Recent moves of note in and around the biotech and pharma industries
続きを読む »